Avalo Therapeutics, Inc. (AVTX) AI Stock Analysis

Avalo Therapeutics, Inc., originally known as Cerecor Inc., is a clinical-stage precision medicine company headquartered in Rockville, Maryland. Founded in 2011, it focuses on developing therapies for unmet clinical needs. Its lead pipeline asset is AVTX-002, a fully human anti-LIGHT monoclonal antibody evaluated in Phase II trials for non-eosinophilic asthma and inflammatory bowel disease, and Phase III trials for COVID-19 acute respiratory distress syndrome. The company is also advancing AVTX-007 in Phase I trials for Still's disease. Its rare genetic disease programs include AVTX-801 in Phase III trials for PGM1 deficiency and AVTX-803 in Phase III trials for LADII.

Avalo Therapeutics generates minimal commercial revenue as its pipeline remains in clinical development. Annual revenue declined from $5.4M in FY2021 and $18.1M in FY2022 down to $1.9M in FY2023, $441,000 in FY2024, and $59,000 in FY2025, reflecting a 5-year revenue CAGR of -61.2%. Net losses remained elevated, moving from -$84.4M in FY2021 to -$41.7M in FY2022, -$31.5M in FY2023, -$35.1M in FY2024, and -$78.3M in FY2025 as FY2025 R&D expenses reached $50.1M. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 69.3% year-over-year, while trailing twelve months revenue stood at $59,000 with EPS of -$4.31.

As of June 30, 2026, Avalo Therapeutics held $400.3M in cash and short-term investments against total debt of $242,000, resulting in net cash of $400.0M. The company reported shareholders' equity of $448.7M, total assets of $490.8M, a current ratio of 19.31, and a debt-to-equity ratio of 0.00. In FY2025, operating cash flow was -$51.5M and free cash flow was -$51.5M, reflecting continued clinical development burn. Capital activities in FY2025 included share issuance of $23,000, while 5-year share count change was 110006.1%.

Avalo Therapeutics trades at a market capitalization of $604.4M and an enterprise value of $420.5M. The stock trades at a price-to-book ratio of 1.8x. In comparison, the median of its US-listed Healthcare peers carries a price-to-book ratio not provided, but displays a trailing P/E of 24.6x, a forward P/E of 17.3x, and a price-to-sales ratio of 4.1x. Over the past year, the stock fell 19.5%, underperforming the S&P 500 return of 16.8%, and stands down 37.9% year-to-date at a closing price of $11.27 on October 16, 2026.

Wall Street sentiment is positive, with 12 Strong Buy ratings, 2 Buy ratings, and zero Hold, Sell, or Strong Sell ratings. The mean price target is $44.08, representing an upside of 291.2% from the last close of $11.27. Consensus estimates project FY2026 EPS of -$2.73 and zero revenue, followed by FY2027 EPS of -$2.71 on zero revenue across 10 covering analysts. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Avalo Therapeutics, Inc. (AVTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AVTX income statement, AVTX balance sheet, AVTX key metrics, AVTX analyst forecast, AVTX chart. See the AVTX stock overview for the latest quote and news.